NCT00943072 - Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO) | Biotech Hunter

Enrollment

189

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

April 30, 2012

Conditions

Macular Edema Secondary to Central Retinal Vein Occlusion

Interventions

BIOLOGICAL

VEGF Trap-Eye 2.0mg

Monthly intravitreal injection out to the Week 24 Primary endpoint

DRUG

Sham

Monthly sham intravitreal injection out to Week 24 Primary Endpoint

Trial Locations (61)

14620

Rochester

15213

Pittsburgh

18704

Kingston

21204

Towson

21209

Baltimore

21740

Hagerstown

27157

Winston-Salem

29169

West Columbia

30909

Augusta

32701

Altamonte Springs

33143

Miami

33334

Fort Lauderdale

33410

Palm Beach Gardens

33880

Winter Haven

33907

Fort Myers

33912

Fort Myers

37203

Nashville

44195

Cleveland

44281

Kfar Saba

48104

Jackson

49100

Petah Tikva

49525

Grand Rapids

57701

Rapid City

60612

Chicago

64239

Tel Aviv

67214

Wichita

68506

Lincoln

73104

Oklahoma City

76100

Rehovot

76102

Fort Worth

77030

Houston

78240

San Antonio

79606

Abilene

85014

Phoenix

85020

Phoenix

85704

Tucson

89135

Las Vegas

90211

Beverly Hills

90503

Torrance

91007

Arcadia

92037

La Jolla

94040

Mountain View

94609

Oakland

95841

Sacramento

97210

Portland

97302

Salem

500034

Hyderabad

560010

Bangalore

700073

Kolkata

06320

New London

02114

Boston

08225

Northfield

08755

Toms River

V5Z 3N9

Vancouver

V8V 4X3

Victoria

B3H 2Y9

Halifax

N6A 4V2

London

L4W 1W9

Mississauga

M4N 3M5

Toronto

Unknown

Medellín

Bogotá